Utilization of the 21-Gene Recurrence Score in a Diverse Breast Cancer Patient Population: Development of a Clinicopathologic Model to Predict High-Risk Scores and Response to Neoadjuvant Chemotherapy

[1]  H. Bear,et al.  Using the 21‐gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial , 2017, Journal of surgical oncology.

[2]  M. Kerin,et al.  Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer , 2017, Breast cancer.

[3]  D. Dabbs,et al.  Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors , 2017, Modern Pathology.

[4]  L. Newman,et al.  Health Disparities and Triple-Negative Breast Cancer in African American Women: A Review , 2017, JAMA surgery.

[5]  R. Heidel,et al.  Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data , 2017, Breast Cancer Research and Treatment.

[6]  Michael R. Harowicz,et al.  Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset , 2017, Breast Cancer Research and Treatment.

[7]  L. Cope,et al.  A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay. , 2015, Clinical breast cancer.

[8]  J. Hainsworth,et al.  A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score , 2015, Breast Cancer Research and Treatment.

[9]  M. Ling,et al.  Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score , 2015, Modern Pathology.

[10]  E. Winer,et al.  Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Kevin A. Henry,et al.  Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State , 2015, Journal of the National Cancer Institute.

[12]  C. Geyer,et al.  Pathological Complete Response in Neoadjuvant Treatment of Breast Cancer , 2015, Annals of Surgical Oncology.

[13]  O. Menyhárt,et al.  Gene expression-based prognostic and predictive tools in breast cancer , 2015, Breast Cancer.

[14]  D. Dabbs,et al.  Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis , 2013, Modern Pathology.

[15]  E. Perez,et al.  Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. , 2012, Journal of the National Cancer Institute.

[16]  E. Mamounas,et al.  Impact of the 21-Gene Recurrence Score Assay Compared With Standard Clinicopathologic Guidelines in Adjuvant Therapy Selection for Node-Negative, Estrogen Receptor-Positive Breast Cancer , 2011, Annals of Surgical Oncology.

[17]  J. Griggs,et al.  A Lower Allred Score for Progesterone Receptor Is Strongly Associated With a Higher Recurrence Score of 21-Gene Assay in Breast Cancer , 2010, Cancer investigation.

[18]  T. Shien,et al.  21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients. , 2009, Breast.

[19]  Rohit Bhargava,et al.  Histopathologic variables predict Oncotype DX™ Recurrence Score , 2008, Modern Pathology.

[20]  Christos Hatzis,et al.  Commercialized multigene predictors of clinical outcome for breast cancer. , 2008, The oncologist.

[21]  Andreas Makris,et al.  Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients , 2008, Breast Cancer Research and Treatment.

[22]  S. Paik.  Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. , 2007, The oncologist.

[23]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[24]  Roman Rouzier,et al.  Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Singletary,et al.  Neoadjuvant chemotherapy in women with invasive breast carcinoma: conceptual basis and fundamental surgical issues. , 2000, Journal of the American College of Surgeons.

[26]  A. Jemal,et al.  Factors That Contributed to Black-White Disparities in Survival Among Nonelderly Women With Breast Cancer Between 2004 and 2013. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. F. Lisa A. Newman MD.  Breast Cancer Disparities: Socioeconomic Factors versus Biology , 2017, Annals of Surgical Oncology.

[28]  A. Soran,et al.  The impact of Oncotype DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer. , 2016, Breast disease.